Related Experiment Videos
Adjunctive use of tolazamide in newly-diagnosed diabetic children
1University of Rochester Medical Center, Department of Pediatrics, New York.
Insights
This study investigated sulfonylureas as adjunctive therapy for new-onset type 1 diabetes in children. Tolazamide did not improve glycemic control but may reduce insulin dosage in juvenile diabetics.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Sulfonylureas are known to potentiate insulin's anabolic effects.
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease requiring lifelong insulin therapy.
- Adjunctive therapies are explored to improve glycemic control and reduce insulin needs in T1DM.
Purpose of the Study:
- To evaluate the efficacy of sulfonylureas, specifically tolazamide, as adjunctive therapy in newly diagnosed pediatric patients with type 1 diabetes.
- To determine if tolazamide impacts glycemic control (HbA1c) and endogenous insulin production (C-peptide) in this population.
- To assess the effect of tolazamide on daily insulin requirements in children with new-onset T1DM.
Main Methods:
- A 15-month, randomized, prospective, double-blind, placebo-controlled study.
- Participants were newly diagnosed children with type 1 diabetes, stratified by age at diagnosis.
- Treatment group received daily oral weight-adjusted tolazamide; control group received placebo.
Main Results:
- No statistically significant difference in HbA1c values between the tolazamide and placebo groups.
- Fasting serum C-peptide levels were not significantly different between the groups.
- The mean daily insulin dose per kilogram was significantly lower in the tolazamide group (P < 0.001).
Conclusions:
- Adjunctive tolazamide therapy does not appear to offer significant therapeutic benefit for glycemic control in newly diagnosed pediatric type 1 diabetics.
- However, the addition of tolazamide may lead to a reduction in daily insulin requirements in this patient group.
- Further research is warranted to explore the potential role of sulfonylureas in managing insulin needs in juvenile diabetes.
Abstract:
Recent data suggests that one of the major actions of sulfonylureas is to potentiate the anabolic cellular effects of insulin. This is the first study to examine the use of sulfonylureas as adjunctive therapy in newly-diagnosed type I diabetic children. A random, prospective, double blind study over 15 months, stratified by age at diagnosis, was conducted. The treatment group (n = 13) received daily oral weight-adjusted tolazamide whereas the control group (n = 11) received placebo. Monthly comparison of the HbA1 values between groups revealed no statistical difference; likewise, the fasting serum C-peptide values were not dissimilar. The mean daily insulin dose per kilogram, however, was less in the tolazamide group (P less than 0.001). The data suggests that the addition of tolazamide may not be of therapeutic benefit in newly diagnosed juvenile diabetics, although insulin requirements may be reduced.